#United States #Oklahoma City #Wheeler Bio #MindImmune #MITI-101

Partnership for Alzheimer’s Innovative Treatment

September 17, 2025 - In a significant advancement in the fight against Alzheimer's disease, Wheeler Bio, a renowned contract development and biomanufacturing organization, has announced a partnership with MindImmune Therapeutics. The collaboration is set to enhance the development of MITI-101, a pioneering treatment aimed at mitigating Alzheimer's disease through ground-breaking methodologies.

Overview of the Partnership

Wheeler Bio's expertise lies in the production of biopharmaceuticals, and their ModularCMC™ platform serves as the backbone for this collaboration. This state-of-the-art platform is tailored to enable rapid and efficient translation of antibody-based therapeutics from discovery phases to clinical trials. As the healthcare landscape faces an unprecedented challenge with neurodegenerative diseases like Alzheimer’s, strategic partnerships like this one are crucial for ushering in innovative treatments.

MindImmune Therapeutics focuses on addressing neuroinflammation, which plays a pivotal role in the progression of Alzheimer's. Their lead program, MITI-101, is specifically designed to prevent certain immune cells (CD11c+ cells) from infiltrating the brain—a process believed to exacerbate neuroinflammation and neuronal damage in Alzheimer’s patients.

What is MITI-101?

MITI-101’s mechanism centers on halting the dangerous migration of peripheral immune cells to the brain. This innovative monoclonal antibody is considered a first-in-class therapeutic approach to target the underlying causes of Alzheimer's. According to Stevin Zorn, President and CEO of MindImmune Therapeutics, this groundbreaking intervention presents a promising alternative to current therapies, aiming to provide new hope for patients suffering from neurodegenerative diseases.

Wheeler Bio’s Role

With an impressive track record, Wheeler Bio has been involved in the development of over 1,400 unique molecules. Their dedication to scientific rigor combined with a high-touch partnership philosophy sets them apart in the industry. This partnership signifies an additional layering of expertise as they work on MITI-101, providing cGMP drug substance manufacturing to ensure that the clinical development stays on track.

Patrick Lucy, President and CEO of Wheeler Bio, expressed excitement over this partnership, emphasizing the critical medical need for Alzheimer’s solutions. By leveraging their ModularCMC platform, they aim to expedite the CMC (Chemistry, Manufacturing, and Controls) efforts integral to advancing MITI-101.

The Future of Alzheimer’s Treatment

As research and development in neurodegenerative diseases progress, collaborations between biomanufacturers and therapeutic innovators become increasingly vital. This partnership signifies not only a strategic alignment but also a commitment to patients and families who battle the realities of Alzheimer’s daily. With a significant unmet need in the realm of Alzheimer’s treatments, MITI-101 could represent a new frontier in therapeutic interventions, aiding in preserving cognitive function and improving patients’ quality of life.

In conclusion, as Wheeler Bio and MindImmune Therapeutics forge ahead, they set the stage for potentially transformative advancements in Alzheimer's care, underscoring the power of collaboration in medical science. Their commitment to addressing the pressing needs within the realm of neuroinflammation shines a light on the promise that innovative therapies hold for the future.

For more information on Wheeler Bio and their innovative ModularCMC platform, visit their website.